We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Published in Oncology

News · October 28, 2011

Exelixis' Cabozantinib Targets Particularly Sick Thyroid Cancer Patients

'The Pink Sheet' DAILY


Further Reading